Federal Register / Vol. 65, No. 229 / Tuesday, November 28, 2000 / Notices 70937

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with section

1301.34 of Title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on July 25, 2000, Cerilliant

Corporation, 14050 Summit Drive, Suite

121, P.O. Box 80189, Austin, Texas

78708–0189, made application to the

Drug Enforcement Administration to be

registered as an importer of the basic

classes of controlled substances listed

below:

Drug Schedule

Cathinone (1235) .......................... I

Methcathinone (1237) .................. I

N-Ethylamphetamine (1475) ........ I

Gamma hydroxybutyric acid

(2010).

I

Ibogaine (7260) ............................ I

Marihuana (7360) ......................... I

Tetrahydrocannabinols (7370) ..... I

Mescaline (7381) .......................... I

4-Bromo-2,5-

dimethoxyamphetamine (7391).

I

4-Bromo-2,5-

dimethoxyphenethylamine

(7392).

I

4-Methyl-2,5-

dimethoxyamphetamine (7395).

I

2,5-Dimethoxyamphetamine

(7396).

I

3,4-Methylenedioxyamphetamine

(7400).

I

3,4-Methylenedioxy-Nethylamphetamine (7404).I

3,4-

Methylenedioxymethamphetamine (7405).

I

4-Methoxyamphetamine (7411) ... I

Psilocybin (7437) .......................... I

Psilocyn (7438) ............................. I

Heroin (9200) ............................... I

Pholcodine (9314) ........................ I

Tilidine (9750) ............................... I

Amphetamine (1100) .................... II

Methamphetamine (1105) ............ II

Amobarbital (2125) ....................... II

Pentobarbital (2270) ..................... II

Cocaine (9041) ............................. II

Codeine (9050) ............................. II

Dihydrocodeine (9120) ................. II

Oxycodone (9143) ........................ II

Hydromorphone (9150) ................ II

Benzoylecgonine (9180) ............... II

Ethylmorphine (9190) ................... II

Meperidine (9230) ........................ II

Methadone (9250) ........................ II

Dextropropoxyphene, bulk (nondosage forms) (9273).II

Morphine (9300) ........................... II

Thebaine (9333) ........................... II

Levo-alphacetylmethadol (9648) .. II

Oxymorphone (9652) ................... II

The firm plans to import small

quantities of the listed controlled

substances for the manufacture of

analytical reference standards.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of these basic classes of

controlled substances may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections or

requests for a hearing may be addressed,

in quintuplicate, to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, DC

20537, Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than December 28, 2000.

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1301.34(b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import the basic classes

of any controlled substances in

Schedule I or II are and will continue to

be required to demonstrate to the

Deputy Assistant Administrator, Office

of Diversion Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1301.34(a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: November 8, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–30294 Filed 11–27–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances;

Notice of Registration

By Notice dated September 1, 2000,

and published in the Federal Register

on September 25, 2000, (65 FR 57621),

Glaxo Wellcome Inc., Attn: Jeffrey A.

Weiss, 1011 North Avendell Avenue,

P.O. Box 1217, Zebulon, North Carolina

27597–2309, made application by

renewal to the Drug Enforcement

Administration (DEA) to be registered as

an importer of remifentanil (9739), a

basic class of controlled substance listed

in Schedule II.

The remifentanil is being imported for

the production of Ultiva dosage forms

and for research and new product

development.

No comments or objections have been

received. DEA has considered the

factors in title 21, United States Code,

section 823(a) and determined that the

registration of Glaxo Wellcome Inc. to

import remifentanil is consistent with

the public interest and with United

States obligations under international

treaties, conventions, or protocols in

effect on May 1, 1971, at this time. DEA

has investigated Glaxo Wellcome Inc. on

a regular basis to ensure that the

company’s continued registration is

consistent with the public interest.

These investigations have included

inspection and testing of the company’s

physical security systems, audits of the

company’s records, verification of the

company’s compliance with state and

local laws, and a review of the

company’s background and history.

Therefore, pursuant to section 1008(a) of

the Controlled Substances Import and

Export Act and in accordance with title

21, Code of Federal Regulations, section

1301.34, the above firm is granted

registration as an importer of the basic

class of controlled substance listed

above.

Dated: November 7, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–30291 Filed 11–27–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to section 1301.33(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on September

6, 2000, ISP Freetown Fine Chemicals,

Inc., 238 South Main Street, Freetown,

Massachusetts 02702, made application

by letter to the Drug Enforcement

Administration (DEA) for registration as

a bulk manufacturer of the basic classes

of controlled substances listed below:

Drug Schedule

2,5-Dimethoxyamphetamine

(7396).

I

Amphetamine (1100) .................... II

Phenylacetone (8501) .................. II